From gathering signatures for Utah’s medical cannabis initiative to becoming only the second person to undergo an experimental cancer treatment, Pam Harrison has spent years stepping forward when others may benefit.

When Pam Harrison learned that an old friend was developing an experimental cancer treatment using antibodies made specifically from the unique mutations found in an individual patient’s tumor, she didn’t need much convincing.

“I want to be in your research; put me in your clinical trial,” Harrison remembers telling David Krag, M.D.

Eventually, he did.

“I want to be in your research; put me in your clinical trial.”

This spring, Harrison temporarily left Utah for Hershey, Pennsylvania, where she became only the second person to undergo the experimental antibody treatment. For roughly 15 weeks, Harrison made Penn State Cancer Institute part of her routine, receiving 10 infusions as one of the earliest participants in a Phase I clinical trial for people with Stage IV cancer.

The study is remarkably small. Researchers plan to treat up to 12 evaluable participants with antibodies created from each patient’s unique tumor mutations. Tumor tissue is sequenced to identify mutated proteins on the surface of cancer cells. Antibodies targeting those mutations are then manufactured and delivered back to the patient through a series of infusions.

The ambition behind the research is enormous. Krag has spent decades studying antibodies and cancer, with the hope that highly personalized treatments like this could eventually provide patients with more targeted and less toxic options.

But this first Phase I trial has a much narrower job: determining whether these patient-specific antibodies can be manufactured and safely administered to humans and whether the approach warrants further study. There is no promise that it will stop Harrison’s cancer.

She understood that when she signed up.

Of course Harrison hopes the treatment works for her. But she also sees value in participating in research that could help scientists learn more about treating cancer for the patients who come after her.

“I’m the second human to have this antibody treatment,” Harrison says. “And so now I am on that guinea pig cycle where they’re trying to figure out what this looks like and how soon do you see results.”

Harrison says she experienced no adverse effects from the infusions. Her treatment days usually began around 7:30 in the morning and stretched into the afternoon.

“As soon as they pulled the needle out of my arm, I’d go do whatever errands I had, or if I wanted to go to the botanical gardens there.”

Spend enough time talking with Harrison and that response begins to sound less surprising.

Long before she volunteered to become one of the first humans to receive an experimental cancer treatment, she was putting herself in the middle of another uncertain fight back home in Utah.

This one involved cannabis, clipboards and thousands of signatures.

A Petition and a Purpose

In 2018, Utah voters were considering several citizen initiatives, including Proposition 2, which sought to establish a legal medical cannabis program.

Harrison was already registering voters at a local farmers market when she learned someone nearby was collecting signatures for the medical cannabis initiative.

“I dashed down there,” she says. “And the next week is when I started collecting signatures.”

She didn’t stop.

Harrison spent nearly every available hour gathering signatures, working farmers markets and community events across Weber and Davis counties. She collected at the State Capitol. She worked multi-day events, including the Eden Balloon Festival and FanX, where she remembers spending all three days gathering signatures from open to close.

“Basically, my life revolved around that,” she says. “I just kept working whenever there was an opportunity.”

According to Utah Patients Coalition Executive Director Desiree Hennessy, Harrison became one of the coalition’s most prolific signature gatherers.

But Harrison noticed something else while standing behind those petitions.

People came looking for medical cannabis.

“Medical cannabis was truly the magnet that carried the other initiatives because people were lined up—literally—to sign the medical cannabis initiative.”

“Medical cannabis was truly the magnet that carried the other initiatives because people were lined up—literally—to sign the medical cannabis initiative,” Harrison says.

Once they had signed Proposition 2, Harrison and other volunteers would introduce them to the Medicaid expansion and independent redistricting initiatives that were also gathering signatures.

“And we’d say, ‘Hey, have you heard of Better Boundaries, and do you know anybody that would benefit from Medicaid expansion?’” she recalls. “And we would explain those, and they’d sign all three.”

All three initiatives eventually qualified for the ballot and were approved by Utah voters in November 2018.

For Harrison, however, election night wasn’t the end of the work.

Utah lawmakers replaced the voter-approved Proposition 2 with the Utah Medical Cannabis Act during a special legislative session the following month, significantly rewriting the framework voters had approved.

Harrison went to the Capitol.

She attended committee hearings, listened to lawmakers and spoke whenever public comment gave her the opportunity. She remained involved as Utah’s medical cannabis program continued to evolve.

“I would talk whenever I would get a chance to,” she says. “We ended up having some humongous committee hearings that took more than one room, and they were very generous with time and let the public have our chance at the mic.”

For Harrison, some of those debates intersected directly with her professional life.

A licensed clinical social worker with a master’s degree and years of experience in mental health, Harrison became involved in discussions surrounding who could diagnose mental health conditions connected to medical cannabis eligibility, including post-traumatic stress disorder. She objected when social workers were initially excluded and advocated for their inclusion before the legislation was finalized.

It was one of many details Harrison learned by showing up repeatedly while Utah’s medical cannabis program took shape.

Years later, the program she had helped fight for would become personal in a way she never anticipated.

The Patient

Harrison first discovered a lump in her breast in 2014.

She pursued several treatments over the years, including cryoablation, but the cancer returned. Along the way, Harrison underwent a double mastectomy.

She talks about the surgery with the same matter-of-fact humor she brings to much of her story.

“Yeah, I don’t care,” she remembers thinking. “I’m old enough. Who needs boobs?”

In 2023, Harrison says, the cancer metastasized, spreading to her bones.

Today she is living with Stage IV metastatic breast cancer.

It is an incurable, life-limiting diagnosis, but Harrison’s day-to-day life bears little resemblance to what many people imagine when they hear the word terminal. She continues to travel, advocate and pursue treatment while living with the uncertainty that accompanies advanced cancer.

The pain from cancer in her bones can be intense.

Harrison has little interest in relying on conventional pain medications. She says she generally avoids them—even common over-the-counter drugs such as ibuprofen and acetaminophen.

Cannabis topicals have become her main tool for managing that pain.

Massaging cannabinoid-infused products into her back, she says, helps make the bone pain manageable.

The advocate who once stood behind a clipboard convincing strangers that Utah patients deserved access to medical cannabis is now depending on that access herself.

Her longtime friend Krag had been working on a different approach to cancer treatment: antibodies customized to mutations found in an individual patient’s tumor.

When Harrison’s cancer progressed, she called him.

“I want to be in your research,” she told him. “Put me in your clinical trial.”

Getting from that phone call to an infusion chair wasn’t quick.

Researchers needed Harrison’s tumor tissue. The antibodies had to be manufactured specifically for her. The clinical trial itself had to move through the regulatory process.

Harrison waited.

Eventually, the opportunity came.

Cancer would send her across the country.

She packed for Pennsylvania.

Human No. 2

The ultimate hope behind cancer research is easy to understand: find treatments that work better and help more people survive.

Getting there is considerably more complicated.

Phase I research occupies an uncomfortable place between scientific possibility and the unknown. At this stage, researchers are trying to determine whether this patient-specific antibody approach can be safely administered to humans before larger studies can more fully examine how well it works.

Harrison is helping them find out.

For her, that meant leaving home for months and receiving 10 infusions at Penn State Cancer Institute in Hershey.

It also meant living in a state where one of the medicines she already relied upon suddenly became difficult to access.

After arriving in Pennsylvania, Harrison called a dispensary expecting that her Utah medical cannabis card—or some form of temporary patient authorization—would allow her to purchase the topical products she used for pain.

It didn’t.

“I was blown away as a cancer patient. You’re telling me I can’t get any lotion rub?” 

“I was blown away as a cancer patient,” Harrison says. “You’re telling me I can’t get any lotion rub?”

She was told she could travel to neighboring states where adult-use cannabis was legal.

The experience gave Harrison a new appreciation for some aspects of Utah’s tightly regulated system, particularly product testing and labeling.

She knew what she wanted: a topical containing cannabinoids such as CBG in a formulation similar to products she used at home. Finding something comparable proved difficult.

“I’m quite glad that we have the testing going on and that it gets that granular,” Harrison says. “How do you know if delta-9 or CBD or CBG or CBN? How do you know unless it’s listed?”

After years spent identifying the shortcomings of Utah’s medical cannabis program, being away from it allowed her to recognize some of what Utah had gotten right.

It didn’t erase the problems she still sees.

Ask Harrison what she would change about Utah medical cannabis today and two things rise quickly to the surface: access and cost.

Those aren’t abstract policy questions anymore.

Neither is medical research.

Harrison is back in Utah after completing her infusions, but her participation in the study continues. Researchers will follow what happens next, watching for adverse effects and gathering information that will help determine whether this highly personalized approach should advance to further study.

There are no guarantees about what the experiment will ultimately mean for Harrison.

There are even fewer guarantees about what researchers may someday learn from her participation for the patients who come after her.

That is how early research works.

Before an experimental treatment can become something physicians routinely offer patients, somebody has to go first.

Then somebody has to go second.

Pam Harrison knows something about joining a cause before anyone can promise how it will turn out.

Years ago, she stood at farmers markets, festivals and crowded convention halls asking Utahns to put their names behind an idea that medical cannabis patients deserved something better.

She stayed for the long days. She went to the Capitol when the law changed. She spoke when lawmakers gave the public a microphone.

Now Harrison is participating in something far more personal.

This time, she didn’t put her name on the line.

She put herself there.

https://www.cannazipbags.com/